Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
Arbidol
COVID-19
Lopinavir/Ritonavir
Novaferon
SARS-CoV-2
interferon
Journal
Clinical and experimental pharmacology & physiology
ISSN: 1440-1681
Titre abrégé: Clin Exp Pharmacol Physiol
Pays: Australia
ID NLM: 0425076
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
23
08
2020
revised:
09
10
2020
accepted:
15
10
2020
pubmed:
23
10
2020
medline:
15
1
2021
entrez:
22
10
2020
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) is an epidemic disease caused by the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) and spreading throughout the world rapidly. Here we evaluated the efficacy of the Lopinavir/Ritonavir (LPV/r) and its combination with other drugs in the treatment of COVID-19. We included 170 confirmed COVID-19 patients who had been cured and discharged. Their antiviral therapies were LPV/r alone or combinations with interferon (IFN), Novaferon and Arbidol. We evaluated the medication efficacy by comparing the time of the negative nucleic acid conversion and the length of hospitalization mainly. The LPV/r + Novaferon [6.00 (4.00-8.00) and 7.50 (5.00-10.00) days] had shorter time of the negative nucleic acid conversion (P = .0036) and shorter time of hospitalization (P < .001) compared with LPV/r alone [9.00 (5.00-12.00) and 12.00 (11.00-15.00) days] and LPV/r + IFN [9.00 (7.25-11.00) and 12.00 (10.00-13.50) days]. On the contrary, LPV/r + IFN [9.00 (7.25-11.00) and 12.00 (10.00-13.50) days] had shorter time of the negative nucleic acid conversion (P = .031) and shorter time of hospitalization (P < .001) compared with LPV/r + IFN +Novaferon [10.00 (8.00-11.25) and 13.50 (11.50-17.00) days] and LPV/r + IFN +Arbidol [14.00 (9.75-19.00) and 19.50 (13.25-24.00) days]. In conclusion, the combination of LPV/r and Novaferon may have better efficacy against COVID-19. However, adding IFN based on LPV/r + Novaferon or adding Arbidol based on LPV/r + IFN may not improve the efficacy.
Identifiants
pubmed: 33090501
doi: 10.1111/1440-1681.13425
doi:
Substances chimiques
Lopinavir
2494G1JF75
Ritonavir
O3J8G9O825
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
203-210Subventions
Organisme : Novel coronavirus pneumonia major project of Hunan
ID : 2020SK3014
Pays : International
Informations de copyright
© 2020 John Wiley & Sons Australia, Ltd.
Références
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-150.
WHO. Coronavirus disease 2019 (COVID-19), Situation Report - 118. Coronavirus disease 2019 (COVID-19) 2020. Accessed 18 May, 2020.
Panoutsopoulos AA. Conjunctivitis as a Sentinel of SARS-CoV-2 Infection: a Need of Revision for Mild Symptoms. SN Comprehensive Clinical Medicine. 2020;2 (7):859-864. http://dx.doi.org/10.1007/s42399-020-00360-7
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824-1836.
Zhang L, Liu YH. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol. 2020;92(5):479-490.
Dong LY, Hu SS, Gao JJ. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60.
Du B, Qiu HB, Zhan X, et al. Pharmacotherapeutics for the new coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):173-176.
Chan KW, Wong VT, Tang SCW. COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative chinese-western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. 2019;2020:1-26.
Panoutsopoulos AA. Known drugs and small molecules in the battle for COVID-19 treatment. Genes & Diseases. 2020;http://dx.doi.org/10.1016/j.gendis.2020.06.007
Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-256.
Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Medicine. 2006;3(9):e343.
Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-347.
Ye XT, Luo YL, Xia SC, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020;24(6):3390-3396.
Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. 2020;81(1):e1-e5.
Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID-19: what's next? Br J Pharmacol. 2020;177(21):4813-4824.
Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020;6:28.
Vankadari N. Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein? Int J Antimicrob Agents. 2020;56(2):105998.
Prokunina-Olsson L, Alphonse N, Dickenson RE, et al. COVID-19 and emerging viral infections: the case for interferon lambda. J Exp Med. 2020;217(5):e20200653.
Chen J, Ling Y, Xi XH, et al. Efficacy of lopinavir/ritonavir and Arbidol for the treatment of new coronavirus pneumonia. Chin J Infect Dis. 2020;2:86-89.
Li M, Rao C, Pei D, et al. Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo. Cancer Cell Int. 2014;14(1):8.
Zheng F, Zhou Y, Zhou Z, et al. A novel protein drug, novaferon, as the potential antiviral drug for COVID-19. medRxiv. https://doi.org/10.1101/2020.04.24.20077735
Su B, Wang Y, Zhou R, et al. Efficacy and tolerability of Lopinavir/Ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing, China. Front Pharmacol. 2019;10:1472.
NHC. Diagnosis and treatment protocol for severe and critical cases of novel coronavirus pneumonia (trial version 2).
Cheng CY, Lee YL, Chen CP, et al. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J Microbiol Immunol Infect. 2020;53(3):488-492.
Yuan J, Zou R, Zeng L, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm Res. 2020;69(6):599-606.
Li F, Xue M, Lu F, Zou Y. [Mechanism of Novaferon on production of TNF-alpha by monocytes isolated from normal human peripheral blood]. Zhong Nan da Xue Xue Bao Yi Xue Ban. 2013;38(1):66-69.
Li F, Wang W, Zhao Z, Zou Y. [Novaferon ameliorates dextran sulfate sodium-induced colitis and downregulates expression of TNF-alpha in mice]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2015;40(5):504-510.
Xu K, Cai H, Shen Y, et al. Management of COVID-19: the Zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):147-157.
Wen CY, Xie ZW, Li YP, et al. Real-world efficacy and safety of lopinavir/ritonavir and arbidol in treating with COVID-19: an observational cohort study. Zhonghua Nei Ke Za Zhi. 2020;59:E012.
Novel Coronavirus Infected Pneumonia Treatment Scheme (Trial Seventh Edition). Infect Dis Inform. 2020;33(1):1-6+26.